Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Alexios Matikas(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Theodoros Foukakis(Karolinska Institutet), Barbro Linderholm(Karolinska University Hospital), Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Elisabet Lidbrink(Stockholm South General Hospital), Hemming Johansson(Karolinska Institutet), Per Karlsson(University of Gothenburg), Per Malmström, Nils‐Olof Bengtsson, Kenneth Villman(Örebro University Hospital), Lena Karlsson(Sundsvall Municipality), Sara Margolin(University of Copenhagen), Per Edlund(Gävle Hospital)
Cited by 8
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k